Sage Ready To Turn Over Cards On Bets Outside Of Depression
Five Clinical Trial Readouts Expected In 2024
Sage has two postpartum depression drugs on the market, but will read out mid-stage trials this year for two candidates in Huntington’s, Parkinson’s and Alzheimer’s diseases and essential tremor.
You may also be interested in...
It’s early days in the launch of Zurzuvae for postpartum depression, but Sage highlighted encouraging prescription trends during the company’s fourth quarter sales and earnings call.
J.P. Morgan Day Four: Roche Sees Lots Of Partnering Interest, While Bluebird, Sage Offer Launch Updates
Daily notebook from the J.P. Morgan Healthcare Conference: Roche expects continued high interest in partnering; Vir explains cost-cutting gives it a stronger base; bluebird provides Lyfgenia performance to date; Sage details Zurzuvae launch trajectory; and Madrigal lays out next steps in NASH.
Sage and Biogen set a $15,900 list price for Zurzuvae, the 14-day postpartum depression drug approved in the US in August, and expect broad access but formulary discussions will continue into 2024.